{"database": "openregs", "table": "federal_register", "rows": [["2017-05245", "Product-Specific Guidances for Rifaximin; Revised Draft Guidance for Industry; Availability", "Notice", "The Food and Drug Administration (FDA, the Agency, or we) is announcing the availability of a revised draft guidance for industry on generic rifaximin oral tablets entitled \"Draft Guidance on Rifaximin.\" The revised draft guidance, when finalized, will provide product-specific recommendations on, among other things, the design of bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs) for rifaximin oral tablets.", "2017-03-16", 2017, 3, "https://www.federalregister.gov/documents/2017/03/16/2017-05245/product-specific-guidances-for-rifaximin-revised-draft-guidance-for-industry-availability", "https://www.govinfo.gov/content/pkg/FR-2017-03-16/pdf/2017-05245.pdf", "Health and Human Services Department; Food and Drug Administration", "221,199", "The Food and Drug Administration (FDA, the Agency, or we) is announcing the availability of a revised draft guidance for industry on generic rifaximin oral tablets entitled \"Draft Guidance on Rifaximin.\" The revised draft guidance, when finalized, will...", null]], "columns": ["document_number", "title", "type", "abstract", "publication_date", "pub_year", "pub_month", "html_url", "pdf_url", "agency_names", "agency_ids", "excerpts", "regulation_id_numbers"], "primary_keys": ["document_number"], "primary_key_values": ["2017-05245"], "units": {}, "query_ms": 0.42731300345622003, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}